Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Next Previous
Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LY 4057996 (Primary) ; Insulin; Insulin degludec; Insulin degludec; Insulin lispro
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 21 Jul 2025 Lispro SC is removed from Active Comparator: Degludec Part B arm. Duration of part B is increased from 5 weeks to 6 weeks.
  • 30 May 2025 Planned End Date changed from 1 Aug 2026 to 1 Dec 2026.
  • 30 May 2025 Planned primary completion date changed from 1 Aug 2026 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top